Nonexudative Age Related Macular Degeneration Clinical Trial
Official title:
Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye
of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD)
will be randomly assigned to receive either topical 1% MC-1101 or a vehicle control over 2
years. The study design will assess the efficacy, safety, and tolerability of MC-1101 for
these patients.
An analysis of the primary and secondary endpoints will be conducted when all subjects have
completed 12, 18 and 24 months.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment